



PRESS RELEASE

Patent Granted for Additional Polymer Technology Originated at Particle Sciences

BETHLEHEM, PA – December 1, 2015 -- Eyeon Therapeutics has received a Notice of Allowance for additional novel dry eye treatments based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO. The product has been shown to be safe and effective in a small trial previously published. Mark Mitchnick, MD, CEO states, "This second set of claims broadens the protection to additional polymers in conjunction with a therapeutic agent. Nanoparticles coated with the novel polymers are also covered. We believe there is very substantial value to this approach and look forward to continuing to help Eyeon develop the technology."

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few effective therapies. Our product offers a unique approach that is clinically validated and useful in a number of ocular applications. In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons."

Particle Sciences, A Lubrizol LifeSciences Company, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at dave@eyeontherapeutics.com

Contact:
Maureen Grieco
610-861-4701
Maureen.grieco@particlesciences.com